Lymphoma  >>  abexinostat (CG-781) 
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
abexinostat (CG-781) / Xynomic
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Recruiting
2
96
RoW
Abexinostat
Xynomic Pharmaceuticals, Inc.
Lymphoma, Follicular
02/24
09/24
FORERUNNER, NCT03600441 / 2018-001701-82: Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Active, not recruiting
2
139
Europe, US
Abexinostat
Xynomic Pharmaceuticals, Inc.
Follicular Lymphoma
12/24
12/25
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
170
RoW
abexinostat
Xynomic Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma (DLBCL)
12/24
05/25
NCT04024696: A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

Active, not recruiting
1/2
12
RoW
Abexinostat
Xynomic Pharmaceuticals, Inc., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non Hodgkin Lymphoma
02/24
06/24
NCT03939182: Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Active, not recruiting
1
15
US
Abexinostat, Ibrutinib
Memorial Sloan Kettering Cancer Center, Janssen Scientific Affairs, LLC, Xynomic Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
05/25
05/25

Download Options